



Cd C
#10

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. : 4,808,614
Issued : February 28, 1989
On an Application of: Larry W. Hertel
Serial No. : 058,219
Filed : June 4, 1987
Entitled : Difluoro Antivirals and Intermediate Therefor
Docket No. : X-5707B

CERTIFICATE

AUG 08 1989

OF CORRECTION

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. 1.322

Commissioner of Patents and Trademarks

Washington, D. C. 20231

Sir:

The patentee of the above-identified patent respectfully request that you issue a Certificate of Correction to correct errors which occurred during the printing of the patent. Attached are two copies of Form PTO 1050 on which the errors are specified.

Respectfully submitted,

[Signature]
Joseph A. Jones
Attorney for Patentee
Registration No. 26,472

Phone: 317-276-5183

APPROVED

JAN 24 1990

[Signature]
FOR THE COMMISSIONER OF PAT. & T.M.

Eli Lilly and Company
Patent Division/JAJ
Lilly Corporate Center
Indianapolis, Indiana 46285

19 July 1989

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,614

Page 2 of 2

DATED : February 28, 1989

INVENTOR(S) : Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16, line 52 insert -- 16 ml -- after "in"

**Signed and Sealed this
Twentieth Day of February, 1990**

Attest:

JEFFREY M. SAMUELS

Attesting Officer

Acting Commissioner of Patents and Trademarks

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,614

Page 1 of 2

DATED : February 28, 1989

INVENTOR(S) : Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2, line 47 "R" in the structure should read -- =0 --

Column 3, line 8 should be a new paragraph.

Column 4, line 3 should read -- 1-[4-amino-5-(2-chlorovinyl)-2-oxo-1H-pyrimidin-1-yl]-2-desoxy-2,2-difluororibose

Column 10, line 61 "CDC13" should read -- CDCl₃ --

Column 14, line 21, "s, 1)" should read -- (s,1H) --

Column 14, line 33 "thanesulfonyloxytri" should read --
thanesulfonyloxytrimethylsilane --

Column 14, line 52 "CD₃OD, 90MH_z) 6" should read --
(CD₃OD, 90MH_z) δ --

Column 15, line 17 "-2,2-difluorori (CD₃OD ...)" should read --
-2,2-difluororibose. nmr (CD₃OD ... --

Column 16, line 37 "MH_z) δ 3.72-4.34 (s,4H)" should read --
MH_z) δ 3.72-4.34 (m,4H), 4.78 (s,4H) --

Column 16, in line 44 delete the figure 6.

Column 16, line 45, insert after "(d," -- J=8 Hz, 1H), 6.3 --

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 4,808,614
DATED : February 28, 1989
INVENTOR(S) : Larry W. Hertel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 2, line 47 "R" in the structure should read -- =0 --
- Column 3, line 8 should be a new paragraph.
- Column 4, line 3 should read -- 1-[4-amino-5-(2-chlorovinyl)-2-oxo-1H-pyrimidin-1-yl]-2-desoxy-2,2-difluoropibose
- Column 10, line 61 "CDC13" should read -- CDC13 --
- Column 14, line 21, "s, 1)" should read -- (s, 1H) --
- Column 14, line 33 "thanesulfonyloxytri" should read -- thanesulfonyloxytrimethylsilane --
- Column 14, line 52 "CD₃OD, 90MH₂) 6" should read -- (CD₃OD, 90MH₂) δ --
- Column 15, line 17 "-2,2-difluorori (CD₃OD ..." should read -- -2,2-difluororibose. nmr (CD₃OD ... --
- Column 16, line 37 "MH₂) δ3.72-4.34 (s, 4H)" should read -- MH₂) δ3.72-4.34 (m, 4H), 4.78 (s, 4H) --
- Column 16, in line 44 delete the figure 6.
- Column 16, line 45, insert after "(d," -- J=8 Hz, 1H), 6.3
- Column 16, line 52 insert -- 16 ml -- after "in"

MAILING ADDRESS OF SENDER:

Eli Lilly and Company
Corporate Center
Indianapolis, Indiana 46285

PATENT NO. 4,808,614

No. of add'l. copies
@ 30¢ per page

